89Zr-AMG211 PET imaging in patients with relapsed/refractory gastrointestinal adenocarcinoma before and during treatment with AMG 211

Trial Profile

89Zr-AMG211 PET imaging in patients with relapsed/refractory gastrointestinal adenocarcinoma before and during treatment with AMG 211

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs MEDI 565 (Primary) ; MEDI 565 (Primary)
  • Indications Adenocarcinoma; Gastrointestinal cancer
  • Focus First in man; Pharmacokinetics
  • Most Recent Events

    • 18 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top